Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.
Metrics to compare | OGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOGENPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.1x | −3.2x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 7.8x | 2.3x | 2.6x | |
Price / LTM Sales | - | 9.8x | 3.3x | |
Upside (Analyst Target) | 52.7% | 202.7% | 43.5% | |
Fair Value Upside | Unlock | 8.7% | 6.9% | Unlock |